Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.43 |
| ▸ | MAPT | P10636 | 8/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 6/20 | 0.42 |
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Resomelagon SCHEMBL30084728 | 1.00 | ALDH1A1 (0.43) | ALDH1A1MAPTSMN1; SMN2GAAKMT2A | |
| Resomelagon SCHEMBL23716726 | 1.00 | ALDH1A1 (0.43) | ALDH1A1MAPTSMN1; SMN2GAAKMT2A | |
| Resomelagon SCHEMBL30064309 | 0.98 | ALDH1A1 (0.42) | ALDH1A1MAPTSMN1; SMN2GAAKMT2A | |
| Resomelagon SCHEMBL30862151 | 0.96 | RAB9A (0.44) | ALDH1A1MAPTSMN1; SMN2GAAKMT2A | |
| Resomelagon SCHEMBL30853066 | 0.95 | ALDH1A1 (0.45) | ALDH1A1MAPTSMN1; SMN2GAAKMT2A | |
| Resomelagon SCHEMBL28929658 | 0.95 | ALDH1A1 (0.45) | ALDH1A1MAPTSMN1; SMN2GAAKMT2A | |
| Resomelagon SCHEMBL22658047 | 0.95 | ALDH1A1 (0.45) | ALDH1A1MAPTSMN1; SMN2GAAKMT2A | |
| Resomelagon SCHEMBL30084718 | 0.93 | NPC1 (0.44) | ALDH1A1MAPTSMN1; SMN2GAAKMT2A | |
| Resomelagon SCHEMBL30084719 | 0.93 | MAPT (0.41) | ALDH1A1MAPTSMN1; SMN2GAAKMT2A | |
| Resomelagon SCHEMBL30065231 | 0.92 | ALDH1A1 (0.45) | ALDH1A1MAPTSMN1; SMN2GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4119140-A1 | COMBINATION TREATMENT OF ARTHRITIC DISEASE | SynAct Pharma ApS (DK) | 2023-01-18 | — | — | EP | disclosed |
| US-20220211666-A1 | COMBINATION TREATMENT OF ARTHRITIC DISEASE | SYNACT PHARMA APS (DK) | 2022-07-07 | — | — | US | disclosed |
| EP-3773558-B1 | COMBINATION TREATMENT OF ARTHRITIC DISEASE | SYNACT PHARMA APS (DK) | 2022-06-15 | — | — | EP | disclosed |
| WO-2020229297-A1 | COMBINATION TREATMENT OF ARTHRITIC DISEASE | SYNACT PHARMA APS (DK) | 2020-11-19 | — | — | WO | disclosed |
| EP-2348016-B1 | Phenyl pyrrole aminoguanidine derivatives | SYNACT PHARMA APS (DK) | 2016-02-17 | — | — | EP | disclosed |
| US-8058306-B2 | Phenyl pyrrole aminoguanidine derivatives | ACTION PHARMA A/S (DK) | 2011-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220211666-A1 | COMBINATION TREATMENT OF ARTHRITIC DISEASE | SYVN1, AP1G1, DNPEP | ALDH1A1 2145/4885MAPT 1543/4885SMN1; SMN2 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.